ARCHIVES

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

Urologists support Approval Of Il-2 for Kidney Cancer

February 1, 1991

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

May 4, 2012

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992

Bush Appoints Seven to NCAB, Designates Runowicz as Chairman.

July 28, 2006

NCI T Fund New Effort By Cooperative Groups To Extend Treatment Into Community Hospitals

March 5, 1976